Trial · NCT07909434
A Study of Mesothelin-Targeted CAR-Mix Cells in Patients With Advanced Solid Tumors
NCT07909434, Phase 1, Not yet recruiting, Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Mesothelin-Targeted CAR-Mix Cells in Patients With Advanced Solid Tumors. Trials, record NCT07909434. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909434
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Mesothelin-Targeted CAR-Mix Cells in Patients With Advanced Solid Tumors
- NCT number
- NCT07909434
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Zhejiang University
- Conditions
- Mesothelin-Positive Advanced Solid Tumors With Peritoneal Metastasis
- Interventions
- SY001
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Dose-Limiting Toxicities (DLTs) | Day 1 through Day 28 after SY001 infusion | DLTs are defined as protocol-specified treatment-related hematologic or non-hematologic toxicities occurring during the 28-day DLT observation period. |
| Primary | Maximum Tolerated Dose (MTD) of SY001 | During the dose-escalation phase, based on DLTs occurring from Day 1 through Day 28 after infusion. | The MTD is defined as the highest dose level at which no more than 1 of 6 evaluable participants experiences a DLT. If the MTD is not reached at the highest planned dose level and no further dose escalation is pursued, the highest evaluated dose may be designated as the MTD according to the protocol. |
| Secondary | Objective Response Rate (ORR) | 6 months | ORR is defined as the proportion of participants who achieve a best overall response of complete response (CR) or partial response (PR), as assessed by investigators according to RECIST Version 1.1. |
| Secondary | Disease Control Rate (DCR) | 12 months | DCR is defined as the proportion of participants who achieve a best overall response of CR, PR, or stable disease (SD), as assessed according to RECIST Version 1.1. |
| Secondary | Duration of Response (DOR) | 12 months | DOR is defined as the time from the first documented CR or PR until the first documented disease progression or death from any cause, whichever occurs first. |
| Secondary | Progression-Free Survival (PFS) | 12 months | PFS is defined as the time from the first SY001 infusion to the first documented disease progression or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | 24 months | OS is defined as the time from the first SY001 infusion to death from any cause. |
| Secondary | Maximum Observed CAR-Mix Copy Number in Peripheral Blood (Cmax) | 28 days | Cmax is defined as the maximum observed CAR-Mix copy number in peripheral blood following SY001 infusion, determined from serial blood samples collected at protocol-specified time points. |
| Secondary | Time to Maximum Observed CAR-Mix Copy Number in Peripheral Blood (Tmax) | 28 days | Tmax is defined as the elapsed time from SY001 infusion to the time at which the maximum CAR-Mix copy number is observed in peripheral blood. Tmax will be expressed in days. |
| Secondary | Area Under the CAR-Mix Copy Number-Time Curve From 0 to Tmax in Peripheral Blood (AUC 0-Tmax) | 28 days | AUC 0-Tmax is defined as the area under the CAR-Mix copy number-time curve in peripheral blood from the time of SY001 infusion to the time of maximum observed copy number (Tmax). |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909434
GET https://conductscience.org/api/trials/v1/NCT07909434/registered